230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

Matthew Krebs; Simon Lord; L. Kenny; Richard Baird; Iain Macpherson; A. Bahl; G. Clack; E. Ainscow; A.G. Barrett; Paul Dickinson; M.J. Fuchter; M. Lehnert; Simak Ali; S. Mcintosh; R.C. Coombes

doi:10.1016/j.annonc.2021.08.513

230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

Matthew Krebs, Simon Lord, L. Kenny, Richard Baird, Iain Macpherson, A. Bahl, G. Clack, E. Ainscow, A.G. Barrett, Paul Dickinson, M.J. Fuchter, M. Lehnert, Simak Ali, S. Mcintosh, R.C. Coombes

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S458
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.513
Publication status	Published - 1 Sept 2021

Access to Document

10.1016/j.annonc.2021.08.513

Cite this

Krebs, M., Lord, S., Kenny, L., Baird, R., Macpherson, I., Bahl, A., Clack, G., Ainscow, E., Barrett, A. G., Dickinson, P., Fuchter, M. J., Lehnert, M., Ali, S., Mcintosh, S., & Coombes, R. C. (2021). 230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies. Annals of Oncology, 32, S458. https://doi.org/10.1016/j.annonc.2021.08.513

@article{0039a2347ad342788bb8076595ab0cf5,

title = "230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies",

author = "Matthew Krebs and Simon Lord and L. Kenny and Richard Baird and Iain Macpherson and A. Bahl and G. Clack and E. Ainscow and A.G. Barrett and Paul Dickinson and M.J. Fuchter and M. Lehnert and Simak Ali and S. Mcintosh and R.C. Coombes",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2021.08.513",

language = "English",

volume = "32",

pages = "S458",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Krebs, M, Lord, S, Kenny, L, Baird, R, Macpherson, I, Bahl, A, Clack, G, Ainscow, E, Barrett, AG, Dickinson, P, Fuchter, MJ, Lehnert, M, Ali, S, Mcintosh, S & Coombes, RC 2021, '230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies', Annals of Oncology, vol. 32, pp. S458. https://doi.org/10.1016/j.annonc.2021.08.513

TY - JOUR

T1 - 230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies

AU - Krebs, Matthew

AU - Lord, Simon

AU - Kenny, L.

AU - Baird, Richard

AU - Macpherson, Iain

AU - Bahl, A.

AU - Clack, G.

AU - Ainscow, E.

AU - Barrett, A.G.

AU - Dickinson, Paul

AU - Fuchter, M.J.

AU - Lehnert, M.

AU - Ali, Simak

AU - Mcintosh, S.

AU - Coombes, R.C.

PY - 2021/9/1

Y1 - 2021/9/1

U2 - 10.1016/j.annonc.2021.08.513

DO - 10.1016/j.annonc.2021.08.513

M3 - Meeting Abstract

SN - 0923-7534

VL - 32

SP - S458

JO - Annals of Oncology

JF - Annals of Oncology

ER -